Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06459921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 10, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Jul 1, 2024 to Dec 1, 2024v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xijing Hospital
179 trials monitored
See 8 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.
Trial Details
NCT Number NCT06459921
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Neoadjuvant Chemotherapy, Sintilimab, Locally Advanced Gastric Cancer
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov